The Fly

Allscripts upgraded to Buy at Argus on expanding margins, attractive valuation

Argus analyst David Coleman upgraded Allscripts to Buy from Hold with a $26 price target. The company’s cloud-based solutions have helped to meet the changing needs of patients and healthcare providers during the pandemic, and its increasing margins should continue to benefit from its fast-growing Veradigm business, the analyst tells investors in a research note. Allscripts shares also appear "attractively valued" at current prices near $18, in the lower half of their 52-week range of $13-$23, Coleman adds.

Published first on TheFly

See the top stocks recommended by analysts >>

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More